Wuxi Biologics, officially known as WuXi AppTec Co., Ltd., is a leading global contract research, development, and manufacturing organisation (CDMO) headquartered in Wuxi, China. Founded in 2010, the company has rapidly expanded its operations across major regions, including the United States and Europe, establishing itself as a key player in the biopharmaceutical industry. Specialising in biologics, Wuxi Biologics offers a comprehensive range of services, from cell line development to commercial manufacturing. Their unique integrated platform streamlines the drug development process, enabling clients to bring innovative therapies to market more efficiently. With a strong commitment to quality and innovation, Wuxi Biologics has achieved significant milestones, including numerous partnerships with leading pharmaceutical companies, solidifying its position as a trusted partner in the global biopharmaceutical landscape.
How does Wuxi Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Wuxi Biologics's score of 54 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Wuxi Biologics reported total greenhouse gas emissions of approximately 198,654,000 kg CO2e, comprising 38,346,000 kg CO2e from Scope 1 and 160,308,000 kg CO2e from Scope 2 emissions. Additionally, Scope 3 emissions included 24,700,000 kg CO2e from business travel, 19,176,000 kg CO2e from employee commuting, and 58,680,000 kg CO2e from fuel and energy-related activities, among other categories. The company has set ambitious climate commitments, aiming to achieve net-zero greenhouse gas emissions across its value chain by 2050. Near-term targets include a reduction of absolute Scope 1 and 2 emissions by 58.8% by 2034 from a 2024 base year, and a 63.8% reduction in Scope 3 emissions related to purchased goods and services per kg of product produced within the same timeframe. Long-term goals include a 90% reduction in both Scope 1 and 2 emissions and Scope 3 emissions by 2050, also from a 2024 base year. Wuxi Biologics' mid-term goal is to reduce Scope 1 and 2 GHG emission intensity by 50% (tonnes/RMB10,000) by 2030 from a 2020 base year. These targets are aligned with the Science Based Targets initiative (SBTi) and are classified under the 1.5°C pathway, demonstrating the company's commitment to addressing climate change effectively.
Access structured emissions data, company-specific emission factors, and source documents
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Scope 1 | 11,042,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 74,361,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Wuxi Biologics is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.